Status:
WITHDRAWN
Optimal Tailored Treatment for H. Pylori Infection
Lead Sponsor:
Incheon St.Mary's Hospital
Conditions:
Helicobacter Pylori Infection
Antibiotic Resistant Infection
Eligibility:
All Genders
19-79 years
Phase:
NA
Brief Summary
The efficacy of the current standard triple therapy is at an unacceptably low level. Resistance to antibiotics is suspected to be the major cause of the low efficacy of standard triple therapy. Point ...
Detailed Description
Patients are randomly assigned to the empirical therapy group and tailored therapy group. The empirical therapy group recieves triple therapy of 7 or 14 days. The tailored therapy group receives trea...
Eligibility Criteria
Inclusion
- consecutive subjects who underwent upper gastrointestinal endoscopy and who had a confirmed diagnosis of H pylori infection
Exclusion
- subjects younger than 18 years old
- subjects with a history of H pylori eradication
- subjects who had previous gastric surgery
- subjects who were pregnant or lactating
- subjects with serious concurrent illness
- subjects who were administered antibiotics, bismuth, or PPIs in the 8 weeks preceding the study
- subjects with a history of allergy to any one of the compounds in this study
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04462133
Start Date
September 1 2020
End Date
October 1 2024
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Incheon St. Mary's Hospital
Incheon, South Korea